178 related articles for article (PubMed ID: 32107626)
21. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
22. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Yoshiya T; Kai Y; Tsutani Y; Mimura T; Konishi K; Takeshima Y; Okada M
Thorac Cancer; 2018 Dec; 9(12):1594-1602. PubMed ID: 30298562
[TBL] [Abstract][Full Text] [Related]
23. Survival Prediction and Adjuvant Chemotherapy Based on Tumor Marker for Stage IB Lung Adenocarcinoma.
Wang Y; Zheng D; Chen T; Zhang J; Yao F; Chen H
Ann Thorac Surg; 2020 Mar; 109(3):927-937. PubMed ID: 31614135
[TBL] [Abstract][Full Text] [Related]
24. Solid Tumor Size of 2 cm Divides Outcomes of Patients With Mixed Ground Glass Opacity Lung Tumors.
Mimae T; Tsutani Y; Miyata Y; Imai K; Ito H; Nakayama H; Ikeda N; Okada M
Ann Thorac Surg; 2020 May; 109(5):1530-1536. PubMed ID: 31981497
[TBL] [Abstract][Full Text] [Related]
25. Prognostic stratification of pathological node-negative lung adenocarcinoma by carcinoembryonic antigen level.
Batmunkh K; Cho S; Yum S; Kim K; Jheon S
Interact Cardiovasc Thorac Surg; 2020 Jun; 30(6):820-826. PubMed ID: 32221597
[TBL] [Abstract][Full Text] [Related]
26. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
28. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
29. [Local recurrence based on size after conservative surgery in breast cancer stage T1-T2. A population-based study].
Martínez-Ramos D; Fortea-Sanchis C; Escrig-Sos J; Prats-de Puig M; Queralt-Martín R; Salvador-Sanchis JL
Cir Cir; 2014; 82(3):252-61. PubMed ID: 25238466
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic study of visceral pleural invasion by pulmonary adenocarcinoma with tumor size ≤3 cm].
Chen TY; Ma HW; Jin RR; Xu C; Hua HJ; Song GX; Zhang WM; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):553-558. PubMed ID: 28810296
[No Abstract] [Full Text] [Related]
31. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer.
Liu AN; Sun P; Liu JN; Ma JB; Qu HJ; Zhu H; Yu CY; Zhang LM
Asian Pac J Cancer Prev; 2012; 13(4):1197-201. PubMed ID: 22799305
[TBL] [Abstract][Full Text] [Related]
34. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
35. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Blanchette PS; Desautels DN; Pond GR; Bartlett JMS; Nofech-Mozes S; Yaffe MJ; Pritchard KI
Breast Cancer Res Treat; 2018 Jul; 170(1):169-177. PubMed ID: 29520532
[TBL] [Abstract][Full Text] [Related]
36. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
Chen X; Fan Y; Xu B
Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
[TBL] [Abstract][Full Text] [Related]
37. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
Cefaro GA; Genovesi D; Trignani M; DI Nicola M
Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
[TBL] [Abstract][Full Text] [Related]
38. Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival.
Berry MF; Gao R; Kunder CA; Backhus L; Khuong A; Kadoch M; Leung A; Shrager J
Clin Lung Cancer; 2018 Jan; 19(1):e47-e51. PubMed ID: 28743420
[TBL] [Abstract][Full Text] [Related]
39. The Frequency and Prognostic Impact of Pathological Microscopic Vascular Invasion According to Tumor Size in Non-Small Cell Lung Cancer.
Shimada Y; Saji H; Kato Y; Kudo Y; Maeda J; Yoshida K; Hagiwara M; Matsubayashi J; Kakihana M; Kajiwara N; Ohira T; Ikeda N
Chest; 2016 Mar; 149(3):775-85. PubMed ID: 26379115
[TBL] [Abstract][Full Text] [Related]
40. Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy.
Li JL; Lin XY; Zhuang LJ; He JY; Peng QQ; Dong YP; Wu JX
Medicine (Baltimore); 2017 Jun; 96(26):e7343. PubMed ID: 28658151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
